Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Myelosuppression“
Suchtreffer
Begriffe & Kennungen
Azacitidine Mylan · 4.8 · Infections Myelosuppression may lead to neutropenia and an increased risk of infection. Serious adverse reacti
Eintrag öffnenBesponsa · 4.8 · 13 For clinical management of myelosuppression/cytopenias, see section 4.4.
Eintrag öffnenBesponsa · 4.8 · Myelosuppression/cytopenias
Eintrag öffnenDovprela (previously Pretomanid FGK) · 4.8 · In the TB-PRACTECAL trial, 52 patients reported ADRs of myelosuppression in the BPaLM arm, out of which 27 (18
Eintrag öffnenDovprela (previously Pretomanid FGK) · 4.8 · In the ZeNix trial, there was a greater incidence of events of myelosuppression, 28.9% versus 13.3%, for the 1
Eintrag öffnenDovprela (previously Pretomanid FGK) · 4.8 · Myelosuppression Myelosuppression is a known adverse reaction of linezolid. In the Nix-TB trial, 37% (very com
Eintrag öffnenGlivec · 4.8 · The adverse reactions were similar in all indications, with two exceptions. There was more myelosuppression se
Eintrag öffnenIclusig · 4.8 · 17 Patients with newly diagnosed Ph+ ALL (PhALLCON Study) Myelosuppression events were reported in 83 % of pon
Eintrag öffnenIclusig · 4.8 · 57 Patients with newly diagnosed Ph+ ALL (PhALLCON Study) Myelosuppression events were reported in 83 % of pon
Eintrag öffnenIclusig · 4.8 · Discontinuation due to myelosuppression was infrequent (thrombocytopenia 4%, neutropenia and anaemia < 1% each
Eintrag öffnenIclusig · 4.8 · Discontinuation due to myelosuppression was infrequent (thrombocytopenia 4%, neutropenia and anaemia < 1% each
Eintrag öffnenIclusig · 4.8 · Myelosuppression In the PACE Study, myelosuppression was commonly reported in all patient populations. The fre
Eintrag öffnenIclusig · 4.8 · Myelosuppression In the PACE Study, myelosuppression was commonly reported in all patient populations. The fre
Eintrag öffnenIclusig · 4.8 · Myelosuppression events were reported in 83% of ponatinib-treated patients in PhALLCON, 63% of ponatinib-treat
Eintrag öffnenIclusig · 4.8 · Myelosuppression events were reported in 83% of ponatinib-treated patients in PhALLCON, 63% of ponatinib-treat
Eintrag öffnenLutathera · 4.8 · Myelosuppression Mostly mild/moderate bone marrow toxicity (myelo-/haematotoxicity) manifested with reversible
Eintrag öffnenMinjuvi · 4.8 · Myelosuppression Treatment with tafasitamab can cause serious or severe myelosuppression including neutropenia
Eintrag öffnenOncaspar · 4.8 · Blood and lymphatic system disorders Oncaspar can cause mild to moderate myelosuppression, and all three blood
Eintrag öffnenOnivyde pegylated liposomal (previously Onivyde) · 4.8 · In NAPOLI-1, 5 of 8 underweight patients experienced a grade 3 or 4 adverse reaction, mostly myelosuppression,
Eintrag öffnenOnivyde pegylated liposomal (previously Onivyde) · 4.8 · Myelosuppression
Eintrag öffnen